| 摘要 |
Disclosed is the use of an antibody or antigen-binding fragment thereof in the manufacture of a medicament for treating a disease or disorder which is prevented, ameliorated, improved or inhibited by removal, inhibition or reduction of human TNF-like ligand 1A (hTL1A) activity, wherein the antibody comprises a heavy chain complementarity determining region 1 (HCDR1), HCDR2, and HCDR3 sequence combination of SEQ ID NO: 20/22/24; and/or a light chain complementarity determining region 1 (LCDR1), LCDR2, and LCDR3 sequence combination of SEQ ID NO: 28/30/32, wherein the sequences are as defined in the complete specification. |
